Literature DB >> 16565526

A case study of negative pressure wound therapy to manage acute necrotizing fasciitis.

James R Phelps1, Rona Fagan, Miguel A Pirela-Cruz.   

Abstract

Acute necrotizing fasciitis is a devastating infectious process that requires immediate surgical debridement. Intravenous antibiotic treatment, hyperbaric oxygen therapy, and wound management are considered the standard of care. Subsequent wound closure is achieved with split-thickness skin grafting, delayed surgical closure, or healing by secondary intention. When a patient refuses additional surgical treatment or is no longer a surgical candidate, as was the case with a patient who presented with acute necrotizing fasciitis caused by Clostridium perfringens in the upper extremity, secondary intention healing is the only treatment option. Following surgery and intravenous antibiotic treatment, her wounds were managed with topical negative pressure wound therapy. No adverse events occurred and the wounds were almost completely healed 63 weeks following surgery. Research to develop evidence-based protocols of care for the closure of these wounds is needed.

Entities:  

Mesh:

Year:  2006        PMID: 16565526

Source DB:  PubMed          Journal:  Ostomy Wound Manage        ISSN: 0889-5899            Impact factor:   2.629


  3 in total

1.  Necrotising fasciitis secondary to perforated rectal adenocarcinoma presenting as a thigh swelling.

Authors:  William David George Evans; Conchubhair Winters; Eshan Amin
Journal:  BMJ Case Rep       Date:  2015-03-30

2.  Application of a Silicone Sheet in Negative-Pressure Wound Therapy to Treat an Abdominal Wall Defect after Necrotizing Fasciitis.

Authors:  Jin Su Shin; Hwan Jun Choi
Journal:  Arch Plast Surg       Date:  2017-01-20

3.  Successful treatment of perineal necrotising fasciitis and associated pubic bone osteomyelitis with the vacuum assisted closure system.

Authors:  Susim Kumar; Mark E O'Donnell; Khalid Khan; Gillian Dunne; P Declan Carey; Jack Lee
Journal:  World J Surg Oncol       Date:  2008-06-24       Impact factor: 2.754

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.